ISPOR Seventh
Annual European Congress
“Focusing on Health Care Costs and
Outcomes in Health Care Decision-Making”
PROGRAM - Sunday, October 24, 2004
12:00 – 13:00
Grand Opening &
Contributed Poster Viewing
13:00 – 13:15
Welcome from the ISPOR President
Lieven Annemans MSc, PhD , 2004-2005 ISPOR President &
Professor, Ghent University, Brussels, BelgiumIntroduction and Congress Objectives
Program Committee Co-Chairs:
Frank Ulrich Fricke PhD, Managing Director, Fricke
& Pirk GmbH, Hamburg , Germany, Wolfgang Greiner PhD,
Associate Professor, University of Hannover, Hannover, Germany,
Arne Heissel PhD, Senior Reimbursement Manager, Spinal,
ENT & SNT, Medtronic Europe Sarl, Tolochenaz, Switzerland
13:15 – 15:00
First Plenary
Session
“BETTER
OUTCOMES BY DISEASE MANAGEMENT PROGRAMMES?”
Moderator: Frank Ulrich Fricke PhD,
Managing Director, Fricke & Pirk GmbH, Nuremburg, Germany
Disease
Management Programs: The concept and Expectations by the
Ministry Dr:
Klaus Theo Schroeder , State
Secretary, Federal Ministry for Health and Social Security, Bonn,Germany
Better
Outcomes - For Whom?
Prof. Dr.
Peter Zweifel , Professor,
University of Zurich,
Zurich, Switzerland
Concepts,
Factors for Success and Failures – Lessons Learned From an HMO :
15:00 – 15:30
Break -
Sponsored by MEDTAP International
15:30 –16:30
Contributed
Workshops I
( 7 workshops
in 6 categories)
Clinical study methodology issues including pharmacoepidemiology
(COS) W1: EVALUATION OF THE COST-EFFECTIVENESS OF INTERVENTIONS TO
CHANGE PROFESSIONAL BEHAVIOUR Davey P Compliance issues (CMP) W2: METHODS FOR MEDICATION COMPLIANCE STUDIES: THE IMPORTANCE OF
STATISTICAL DISTRIBUTIONS Nichol MB 1 , Gwadry-Sridhar F2 ,
Benner J3 , Cramer J4 1 2 3 4 Cost study methodology issues (CS)
W3: BAYESIAN NETWORKS, INFLUENCE DIAGRAMS AND THEORETIC DECISION
MODELS IN HEALTH ECONOMICS Baio G 1 , Jansen J 2 , Van
Genugten ML 2 1
2 MAPI Values, Houten, The Netherlands Formulary development research
issues (FS) W4: THE ART AND SCIENCE OF BUDGETARY IMPACT MODELING FOR
FORMULARY SUBMISSIONS Taylor DC , Thompson D Health care policy development
issues using outcomes research (HP) W5: EQUITY AND THE IMPACT OF POLICY ON PATIENT ACCESS TO
MEDICINES: WHAT IS ACCEPTABLE VARIATION? Kerrigan J , Costello S Health care policy development
issues using outcomes research (HP) W6: DISCRETE EVENT SIMULATION TO IMPROVE DECISION MAKING Hout van BA 1 , Heeg BM2 , Botteman M2 1 2 Bethesda,
MD, USA Patient registry development issues
(PR) W7: UTILIZING PATIENT REGISTRIES TO SUPPORT OUTCOMES RESEARCH:
INTEGRATING OBSERVATIONAL DATA WITHIN ECONOMIC ANALYSES, MODELS,
AND OTHER APPLICATIONS Larson LR 1 , Noe L 1 ,
Mathias SD 2 , Waller HD1 , Becker RV1 1 2
16.30 –17.00
17.00 – 1 8.00 Contributed
Workshops II (7 workshops
in 5 categories)
Clinical
study methodology issues including pharmacoepidemiology (COS)
W8:
ESTIMATING LIFE-EXPECTANCY ACCOUNTING FOR SUBJECT-SPECIFIC
CHARACTERISTICS Caro JJ 1 , Ishak K 2 ,
Proskorovsky I 2 1 Caro Research Institute, Concord, MA, USA; 2 Caro
Research Institute, Dorval, QC, Canada
Compliance
issues (CMP)
W9: METHODS
FOR MEDICATION COMPLIANCE STUDIES: AN OVERVIEW OF THE ISPOR
MEDICATION COMPLIANCE SIG GUIDELINES Nau DP 1 , Peterson A 2 ,
Cramer J 3 1 University of Michigan, Ann Arbor, MI, USA; 2 University
of the Sciences in Philadelphia, Philadelphia, PA, USA; 3 Yale
University, New Haven, CT, USA
Cost study
methodology issues (CS)
W10: CODING
PRACTICES AND PROBLEMS THAT CAN ALTER A COST ESTIMATE
O'Brien JA
Cost study
methodology issues (CS)
W11: PROS
AND CONS OF DIFFERENT MODELING TECHNIQUES FROM THE END-USER
PERSPECTIVE Mesrobian X 1 , Van Genugten ML 2 1 MAPI values, Boston, MA, USA; 2 Mapi
Values, Houten, The Netherlands
Health care
policy development issues using outcomes research (HP)
W12: GEP
(GOOD EPIDEMIOLOGICAL PRACTICE)- COMING TO YOUR OFFICE NEXT Parkinson J Davey P
Health care
policy development issues using outcomes research (HP)
W13:
CAPTURING THE VALUE OF PHARMACEUTICALS: THE ROLE OF OUTCOMES
RESEARCH IN PRICING DECISIONS Tierce J 1 , Negrini C 2 ,
Lloyd A 3 , Grueger J 4
1 ValueMedics
Research, LLC, Arlington, VA, USA; 2 PBE Consulting,
s.r.l, Milano, Italy; 3 Fourth Hurdle Consulting, Ltd,
London, UK; 4 Novartis Pharma AG, Basel, Switzerland
Quality of
life study methodology issues including patient reported
outcomes (QOL)
W14:
SCREENERS, SYMPTOM AND DISABILITY SCALES FOR USE IN CLINICAL
PRACTICE: THEIR CONTRIBUTION TO IMPROVE THE USE OF DRUGS Arnould B 1 , De la Loge C 1 ,
Abetz L 2 , Regnault A 3 ,
Duru G 4 1 Mapi Values, Lyon, France; 2 Mapi Values
Ltd, Macclesfield, Cheshire, UK; 3 Université Lyon 1,
Villeurbanne, France; 4 Université C. Bernard Lyon I,
Villeurbanne, France
18.00-20.00
Exhibitors’ Open House Reception, Poster Presentations –
Session ISee Poster
Presentations – Session I
19.00
Advisory Board
Dinner (by invitation only)
HAMBURGER ZIMMER
(RADISSON)
7th Annual European Congress Main Page
